Next Article in Journal
Assessment of Psyllid Handling and DNA Extraction Methods in the Detection of ‘Candidatus Liberibacter Solanacearum’ by qPCR
Previous Article in Journal
Novel Mobile Integrons and Strain-Specific Integrase Genes within Shewanella spp. Unveil Multiple Lateral Genetic Transfer Events within The Genus
Previous Article in Special Issue
Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition
 
 
Review

Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies

1
ISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain
2
CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editors: Grzegorz Wegrzyn and Ute Römling
Microorganisms 2022, 10(6), 1103; https://doi.org/10.3390/microorganisms10061103
Received: 11 May 2022 / Revised: 23 May 2022 / Accepted: 24 May 2022 / Published: 26 May 2022
(This article belongs to the Special Issue Feature Papers in Microbial Biofilm Formation)
Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more resistant to antibiotics and to evade the action of the host’s immune system. For this reason, biofilm-related infections are very difficult to treat. To develop new strategies against biofilms, it is important to know the mechanisms involved in their formation. In this review, the different steps of biofilm formation in E. coli, the mechanisms of tolerance to antimicrobials and new compounds and strategies to combat biofilms are discussed. View Full-Text
Keywords: Escherichia coli; biofilms; resistance; clinical importance; non-traditional approaches Escherichia coli; biofilms; resistance; clinical importance; non-traditional approaches
Show Figures

Figure 1

MDPI and ACS Style

Ballén, V.; Cepas, V.; Ratia, C.; Gabasa, Y.; Soto, S.M. Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies. Microorganisms 2022, 10, 1103. https://doi.org/10.3390/microorganisms10061103

AMA Style

Ballén V, Cepas V, Ratia C, Gabasa Y, Soto SM. Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies. Microorganisms. 2022; 10(6):1103. https://doi.org/10.3390/microorganisms10061103

Chicago/Turabian Style

Ballén, Victoria, Virginio Cepas, Carlos Ratia, Yaiza Gabasa, and Sara M. Soto. 2022. "Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies" Microorganisms 10, no. 6: 1103. https://doi.org/10.3390/microorganisms10061103

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop